Navigation Links
Stem Cell Therapy to Skyrocket by 2017
Date:9/13/2007

Although still in its infancy, stem cell therapy market to grow rapidly

over next decade

WALTHAM, Mass., Sept. 13 /PRNewswire/ -- Millennium Research Group (MRG) has conducted a detailed analysis of the stem cell therapy market in its US Markets for Stem Cell Therapies 2007 report. The analysis reveals that although the market for stem cell therapies is in its infancy, it will grow rapidly as products are approved in the US. Today, only two products are on the market, but by 2017, almost 90 are expected to be available.

Stem cells have regenerative capabilities, and promise lasting treatments for chronic disorders and potential cures for currently 'incurable' diseases. In 2007, the US stem cell therapies market earned over $25 million in revenues, with only two orthopedic products available in the US-Osiris Therapeutics' Osteocel, and Blackstone Medical's Trinity. Aside from these two products, the development of the US market for stem cell therapies is largely dependent on the success of clinical trials, regulatory approval, and public acceptance. The first products in the cardiovascular, diabetes, neurological, and tissue and organ stem cell therapy markets are expected to enter the market between 2009 and 2013. The entry of these products will open up a new realm of treatable disorders, offering hope to patients and vast market potential.

"This market has almost everything going its way", says Chris Schutz, senior analyst at MRG. "The big question mark however is the political and public support. The prevalence of potentially treatable disorders, unmet medical needs, rising health care costs, growth in the aging population, and the success of the first stem cell therapy products are all factors that will drive this market upward through 2017."

The US Markets for Stem Cell Therapies 2007 report includes coverage of companies offering or developing products for the stem cell therapy market, including Aas
'/>"/>

SOURCE Millennium Research Group
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. TomoTherapy opens technical training center
4. TomoTherapy raises $223 million in IPO
5. TomoTherapy revises IPO money target
6. Stem cell therapy shows visionary promise
7. Hospital named for Madame Curie installs TomoTherapy system
8. TomoTherapy files registration statement for IPO
9. TomoTherapy to sell medical devices in India
10. TomoTherapy sees sustained market advantage
11. Mirus granted European patent for gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... Review - 2014 Summary Global Markets ... Review - 2014, provides an overview of the ... focus. This report provides comprehensive information on ... Biotechnology, LLC,s, complete with comparative analysis at various ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... September 30, 2014 Genedata, ... for drug discovery and related life science ... has chosen Genedata Selector as its host-pathogen ... data. FUNGITECT is a European consortium dedicated ... diseases via individualized anti-fungal drug therapies. Genedata ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... The Foundation of UMDNJ, an affiliate of New Jersey ... through the Bill & Melinda Gates Foundation,s Grand Challenges ... overcome persistent bottlenecks in creating new tools that can ... With the grant, Dr. David Alland, professor of ...
... ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused ... and protein products for the industrial enzyme, bioenergy, and ... FibreZyme® G5000, a next generation, high performance ... quality and improve the economics of various pulp and ...
... ARBOR, Mich., March 14, 2012 Synthetic Biologics, ... developer of synthetic DNA-based therapeutics and innovative disease-modifying ... enrollment has been completed in a Phase II ... Synthetic Biologics, proprietary oral formulation of estriol (Trimesta™) ...
Cached Biology Technology:Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 2Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant 3Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference 2Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference 3Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 2Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 3Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 4
(Date:9/29/2014)... September 29, 2014 -- Plants have a symbiotic ... the pants extract nutrients and defend against invaders ... contaminating fruits and vegetables. Now, scientist have discovered ... of seeds; thus ensuring that sprouting plants are ... University of Notre Dame, presented their findings today ...
(Date:9/29/2014)... school? According to a new Food and Brand Lab ... can increase participation in the National School Lunch Program ... vegetables by 16%! , Chefs Move to Schools (CMTS), ... chefs with schools in order to provide nutrition instruction ... service workers. , A CMTS event was held in ...
(Date:9/29/2014)... to support the world,s needs to make cheaper ... new and more efficient catalytic materials and processes ... several from Wayne State University, is tackling this ... from the National Science Foundation. , The nearly ... Materials for Electrocatalytic Cascade Reactions," was to Eranda ...
Breaking Biology News(10 mins):Plants prepackage beneficial microbes in their seeds 2Chefs move to schools can increase school meal participation and vegetable intake among students 2Wayne State research aims to develop new, more efficient catalytic materials 2
... news release is available in German . ... remembering painful lessons in German or Latin grammar in school. Languages ... correctly makes the difference between something which "sounds good", and something ... have shown that sensitivity to very simple structural and melodic patterns ...
... list that was established by the EU Scientific ... European young investigators network for Usher syndrome (EUR-USH) ... University Mainz for funding. Out of 82 submitted ... projects that were chosen after a competitive two-step ...
... they have found ,missing heat, in the climate system, casting ... over the past decade. , Observational data on which ... the planet with Polar regions and parts of Africa ... the University of York, and Robert Way, a cryosphere specialist ...
Cached Biology News:Monkeys 'understand' rules underlying language musicality 2European young investigators network for Usher syndrome awarded E-Rare collab project 2'Missing heat' discovery prompts new estimate of global warming 2
... Pipette Tracker is an automated solution for ... and performance testing for all pipettes and ... from any balance Supports all ... 8655, DIN 12650, ISO 9000, NCCLS and ...
... Activins are polypeptide hormones which ... (TGF-) superfamily. The TGF- superfamily is ... factors which control many aspects of ... (1). Other members incude TGF-s, bone ...
... Activins are polypeptide hormones which belong ... superfamily. The TGF- superfamily is a ... which control many aspects of development, ... Other members incude TGF-s, bone morphogenetic ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
Biology Products: